Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Full-spectrum Medical Canabis Product (HemPhar) With a CBD:THC Ratio of 10:1 for Treatment of Spasticity in Children and Young Adults With Severe Forms of Cerebral Palsy

NCT04634136 is registered in ClinicalTrials.gov with University Medical Centre Ljubljana as lead sponsor.

NCT NCT04634136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04634136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Full-spectrum Medical Canabis Product (HemPhar) With a CBD:THC Ratio of 10:1 for Treatment of Spasticity in Children and Young Adults With Severe Forms of Cerebral Palsy
Lead sponsor
University Medical Centre Ljubljana
Phase
Not applicable
Overall status
Completed
Start date
October 15, 2020
Completion date
February 29, 2024
Enrollment
55 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cannabis, children, adult, physical disability, quality of life, spastic cerebral palsy